Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1161/hypertensionaha.113.01310 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Up-to-Date Snapshot of Current and Emerging Medical Therapies in Primary Biliary Cholangitis.
J Pers Med
November 2024
Healthpoint Hospital, Abu Dhabi 112308, United Arab Emirates.
Primary biliary cholangitis (PBC) is an autoimmune chronic cholestatic disease of the liver that symptomatically can present with pruritus and fatigue. Its established first- and second-line therapies are ursodeoxycholic acid (UDCA) and obeticholic acid (OCA) although they provide limited symptom management. Liver transplantation offers a potentially curative therapeutic option in refractory cases progressing to cirrhosis.
View Article and Find Full Text PDFPrimary Biliary Cholangitis: personalizing second-line therapies.
Hepatology
November 2024
Department of Medicine, Division of Gastroenterology and Hepatology, University of California Davis School of Medicine, Sacramento, California, USA.
Article Synopsis
- Primary biliary cholangitis (PBC) is an autoimmune disease primarily affecting middle-aged women, characterized by damage to small bile ducts, leading to liver issues like cholestasis and cirrhosis.
- The main treatment for PBC has been ursodeoxycholic acid, which helps slow disease progression but doesn't alleviate symptoms; new second-line therapies are being developed for patients who don't respond well.
- Recent medications like obeticholic acid, elafibranor, and seladelpar show promise in improving liver function and reducing cholestasis, while considerations for personalized treatment based on patient features are essential.
Administration time modify the anxiolytic and antidepressant effects of inulin via gut-brain axis.
Int J Biol Macromol
December 2024
College of Food Science and Technology, Key Laboratory of Environment Correlative Food Science, Huazhong Agricultural University, Wuhan 430070, China.. Electronic address:
An imbalance in the microbiota-gut-brain axis exerts an essential effect on the pathophysiology of depressive and anxiety disorders. Our previous research revealed that the timing of inulin administration altered its effects on chronic unpredictable mild stress (CUMS)-induced anxiety and depression. However, it is still unclear if the gut-brain axis is primarily responsible for these effects.
View Article and Find Full Text PDFFenofibrate as an Adjunct Therapy for Ulcerative Colitis: Targeting Inflammation via SIRT1, NLRP3, and AMPK Pathways: A Randomized Controlled Pilot Study.
Drug Des Devel Ther
November 2024
Department of Clinical Pharmacy, Faculty of Pharmacy, University of Sadat City (USC), Sadat City, Menoufia, Egypt.
Background: Ulcerative colitis (UC) is an idiopathic chronic inflammation of colonic and rectal mucosa. The peroxisome proliferator-activated receptor α (PPARα) has been identified as having protective effects in UC.
Aim: The study aimed to investigate the efficacy of fenofibrate, a PPARα agonist, in UC.
Anti-inflammatory potential of aspergillus unguis SP51-EGY: TLR4-dependent effects & chemical diversity via Q-TOF LC-HRMS.
BMC Biotechnol
September 2024
Chemistry of Natural and Microbial Products Department, National Research Centre, Giza, 12622, Egypt.
Inflammation serves as an intricate defense mechanism for tissue repair. However, overactivation of TLR4-mediated inflammation by lipopolysaccharide (LPS) can lead to detrimental outcomes such as sepsis, acute lung injury, and chronic inflammation, often associated with cancer and autoimmune diseases. This study delves into the anti-inflammatory properties of "Aspergillus unguis isolate SP51-EGY" on LPS-stimulated RAW 264.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!